摘要
目的探讨人单核细胞THP-1源性巨噬细胞产生的Lipocalin型前列腺素D合酶(lipocalin typeprostaglandin D synthase,L-PGDS)、前列腺素E2(prostaglandin E2,PGE2)和前列腺素D2(PGD2)与载脂蛋白A-Ⅰ(apolipoprotein A-Ⅰ,apoA-Ⅰ)抗动脉粥样硬化(atherosclerosis,AS)作用之间的关系。方法采用MTT法确定合适的给药浓度。用不同浓度(0、12.5、25、50、100和200μg/mL)apoA-Ⅰ处理体外培养的THP-1细胞源性巨噬细胞24 h后,逆转录-聚合酶链式反应法(RT-PCR)检测L-PGDS mRNA表达的变化,酶联免疫测定法(ELISA)检测PGE2和PGD2蛋白表达的变化。结果 apoA-Ⅰ处理24 h的巨噬细胞中L-PGDS mRNA、PGE2和PGD2蛋白的表达均显著高于未用apoA-Ⅰ处理的巨噬细胞(P均<0.001);apoA-Ⅰ浓度为50μg/mL时,作用效果最明显。结论 apoA-Ⅰ的抗AS作用可能与上调THP-1细胞源性巨噬细胞中L-PGDS mRNA以及PGE2和PGD2蛋白的表达有关。
Objective To explore the effect of apolipoprotein （apo） A- I on production of lipocalin- type prostaglandin D synthase （ I.-PGDS）, prostaglandin E2 （ PGE. ） and prostaglandin D2 （ P（;D2 ） by human monocyte-derived macrophage as well as their relationship with anti-atherosclerotic effect of apoA- I . Methods The suitable concentrations of apoA-1 used to this research were determined by MTT method. Human monocyte-derived macrophage were incubated with apoA-I at different concentrations （11,12.5,25,511,100 and 200 ug/mL） for 24 hours. L-PGDS expression in these cells was then analyzed at mRNA level by RT-PCR. PGE2 and PGD2 production in cell culture supernatant was measured at protein level by enzyme immunoassay, respectively. Results L-PGDS mRNA expression and PGE2, PGD2 productions were increased in apoA-I incubated （ 12. 5,25,511,100 and 2011 μg/ml macrophage compared with the control,respectively （P〈0.001 ）. And the effect of apoA-] was the most obvious al concentration of 511 μg/mL. Conclusions Apolipoprotein A- I up-regulales I.-PGDS mRNA expression and enhances PGE2 and PGD, synthesis by human monocyte-derived macrophages, which might be involved in thc anti-atherosclerotic effect of apoA- I
出处
《复旦学报（医学版）》
CAS
CSCD
北大核心
2013年第1期10-14,共5页
Fudan University Journal of Medical Sciences
基金
国家自然科学基金项目(30973684)
上海市科委资助项目(0952nm03500)~~
